Upstream Bio, Inc. (NASDAQ:UPB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $45.25.

Several equities analysts have commented on UPB shares. Truist Financial started coverage on shares of Upstream Bio in a research note on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price target on the stock. Lifesci Capital started coverage on shares of Upstream Bio in a research report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, October 8th. Evercore ISI began coverage on shares of Upstream Bio in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Mizuho raised Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th.

Institutional Investors Weigh In On Upstream Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Upstream Bio in the second quarter valued at approximately $10,650,000. Marshall Wace LLP boosted its stake in Upstream Bio by 198.8% during the 3rd quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock worth $16,327,000 after purchasing an additional 577,473 shares during the period. Integral Health Asset Management LLC purchased a new position in Upstream Bio during the 3rd quarter worth $10,816,000. Vanguard Group Inc. grew its position in Upstream Bio by 12.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock worth $45,944,000 after purchasing an additional 271,718 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Upstream Bio by 57.5% in the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after purchasing an additional 235,958 shares during the period.

Upstream Bio Price Performance

Upstream Bio stock opened at $31.13 on Thursday. The stock has a market cap of $1.68 billion, a PE ratio of -16.56 and a beta of 1.83. The stock’s fifty day moving average is $25.91 and its two-hundred day moving average is $18.94. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.00.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.65 million. On average, research analysts expect that Upstream Bio will post -4.3 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.